Brief: Renovorx Enrolls First Patient In Ongoing Tiger-Pac Phase 3 Clinical Trial
22/02/2022 13:39
Feb 22 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ENROLLS FIRST PANCREATIC CANCER PATIENT AT
COLUMBIA
UNIVERSITY’S NEW YORK-PRESBYTERIAN HOSPITAL IRVING MEDICAL
CENTER IN ONGOING TIGER-PAC PHASE 3 CLINICAL TRIAL
Source text for Eikon: ID:nBw7dhK4xa
Further company coverage: RNXT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies